Cargando…

A clinical evaluation of Kanchanara Guggulu and Bala Taila Matra Basti in the management of Mutraghata with special reference to benign prostatic hyperplasia

BACKGROUND: Mutraghata a disease of Mutravaha Srotasa (urinary system) described in Ayurveda, closely resembles with benign prostatic hyperplasia (BPH) of the modern medicine. It affects man above the age of 40 years. Conservative management with hormonal therapy, open prostatectomy and TURP are the...

Descripción completa

Detalles Bibliográficos
Autores principales: Banothe, Gajiram Dharamdas, Mahanta, Vyasdeva, Gupta, Sanjay Kumar, Dudhamal, Tukaram S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369605/
https://www.ncbi.nlm.nih.gov/pubmed/30783359
http://dx.doi.org/10.4103/ayu.AYU_117_15
Descripción
Sumario:BACKGROUND: Mutraghata a disease of Mutravaha Srotasa (urinary system) described in Ayurveda, closely resembles with benign prostatic hyperplasia (BPH) of the modern medicine. It affects man above the age of 40 years. Conservative management with hormonal therapy, open prostatectomy and TURP are the options available in modern medicine. In Ayurveda, the drugs having Vata Kapha pacifying action, Shothahara (anti-inflammatory) and Mutrala (diuretic) are recommended for its management. AIM: The aim of this study was to evaluate the clinical efficacy of Kanchanara Guggulu orally and Bala Taila Matra Basti in the management of Mutraghata (BPH). MATERIALS AND METHODS: A total of 32 selected patients were divided into two groups. In group A, Bala Taila 60 ml, Matra Basti, once a day, was administered just before breakfast for 21 days. In group B, Bala Taila (60 ml), Matra Basti, once a day, was administered just before breakfast for 21 days and Kanchanara Guggulu Vati 1g (2 tab, 500mg each) three times a day, orally with lukewarm water was administered for 21 days. Findings were recorded in research proforma at weekly interval and patients were followed up till 1 month. RESULTS: In group A, the maximum improvement was seen in 3 patients (25.00%), moderate improvement was seen in 8 patients (66.67%) and mild improvement was observed in 1 patient (8.34%). Similarly, in group B, the maximum improvement was found in 10 patients (55.56%), moderate improvement in 7 patients (38.89%) and mild improvement in 1 patient (5.56%) only. None of the patients got complete remission or remained unchanged in either of the groups. Significant reduction was observed in postvoidal residual urine volume and the size of the prostate in both the groups. CONCLUSION: It was concluded that Matra Basti along with Kanchanara Guggulu orally showed Mutraghata comparatively better symptomatic relief as compared to Matra Basti alone in cases of Mutraghata (BPH).